Navigating China's Volume-Based Procurement in the Pharma Industry

China’s Volume-Based Procurement (VBP) tenders have already sliced average drug prices by 50 %+, saving the system US $60 billion and redirecting ≈80 % of that to fund innovative therapies.

In this video briefing, L.E.K. Partner Helen Chen shows why VBP is now a permanent fixture and outlines a three-phase playbook to preserve brand value as volumes and margins tighten.

Watch the video for Helen’s data-backed guidance and concrete next steps for pharmaceutical leaders navigating China’s evolving market.

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2025 L.E.K. Consulting LLC